Related Experiment Video
Updated: Apr 20, 2026
Glomerular Outgrowth as an Ex Vivo Assay to Analyze Pathways Involved in Parietal Epithelial Cell Activation
Published on: August 19, 2020
Recurrent Focal Segmental Glomerulosclerosis and Abatacept: Case Report
Omar Alkandari1, Narayanan Nampoory, Prasad Nair
1From the Division of Pediatric Nephrology, Mubarak Al-Kabeer Hospital; and the Division of Nephrology, Hamid Al-Essa Organ Transplant Center, Sabah Health Region, Shuwaikh, Kuwait.
Abatacept treatment failed to resolve recurrent focal segmental glomerulosclerosis (FSGS) in a pediatric kidney transplant patient. Its efficacy in B7-1-negative FSGS recurrence remains uncertain.
Area of Science:
- Nephrology
- Pediatric Nephrology
- Transplant Immunology
Background:
- Focal segmental glomerulosclerosis (FSGS) is a leading cause of end-stage renal disease in children.
- Recurrence of FSGS post-kidney transplant presents significant challenges, potentially leading to graft dysfunction and loss.
- Current therapies for recurrent FSGS show variable responses, with some cases resistant to all treatments.
More Related Videos
06:35An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
Published on: February 8, 2019
07:15Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
Published on: August 23, 2024